エピソード

  • S8:E2 – Getting a Grip on CIDP
    2024/06/22

    In this episode, Getting a Grip on CIDP, Dr. Diana Castro and Dr. Jeffrey Allen discuss some of the latest presentations and clinical data coming out of the 2024 American Academy of Neurology meeting.

    Visit https://suitehome.atpointofcare.com/library/2639.12/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    続きを読む 一部表示
    19 分
  • S8:E1 – A Deeper Look at CIDP Diagnosis and Treatment
    2024/06/21

    In this episode, A Deeper Look at CIDP Diagnosis and Treatment. Dr. Diana Castro and Dr. Jeffrey Allen discuss diagnosing CIPD with a focus on updates to the current guidelines for optimal treatment and management. Visit https://suitehome.atpointofcare.com/library/2639.11/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

    続きを読む 一部表示
    26 分
  • S7:E3 – Morning Commute Podcast: Worth the Risk? Using Anti-Amyloid Therapies for Alzheimer’s Disease
    2023/12/15

    In this episode our faculty take a look at the treatment-related side effects associated with some of the newer treatments for Alzheimer’s disease, with a focus on amyloid-related imaging abnormalities (ARIA). How do you weigh the risk and benefits for your patients?

    Visit www.morningcommutepodcast.com/alzheimers3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

    続きを読む 一部表示
    28 分
  • S7:E2 – Morning Commute Podcast: Untying the Beta-Amyloid Knots in Alzheimer’s Disease
    2023/12/15

    In this podcast, our faculty discuss talk some of the newer treatments for Alzheimer's disease, especially anti-beta-amyloid antibody treatments.

    Visit www.morningcommutepodcast.com/alzheimers2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

    続きを読む 一部表示
    27 分
  • S7:E1 – Morning Commute Podcast: Drawing a Blank: When Does a Patient’s Forgetfulness Signal a Concern it Might Be Alzheimer’s Disease?
    2023/12/15

    When is a patients cognitive difficulties a signal that they may be on the road to Alzheimer's disease? Our faculty discuss some of the recent advances making this diagnosis.

    Visit www.morningcommutepodcast.com/alzheimers1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

    続きを読む 一部表示
    27 分
  • S2:E8 – Neurology Morning Commute: Multiple Sclerosis and the S1P Receptor Upgrade
    2022/04/11

    In this episode, our faculty looks at the latest treatments for multiple sclerosis—the newest sphingosine-1-phosphate receptor modulators. What is their mechanism of action? Which patients would benefit from them, and how are side effects and toxicities managed with these latest treatment options?

    Visit www.morningcommutepodcast.com/ms8 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    続きを読む 一部表示
    23 分
  • S2:E7 – Neurology Morning Commute: Getting UP to Speed on Multiple Sclerosis Management
    2022/04/11

    With the many treatments now available for the treatment of multiple sclerosis (MS), our faculty reviews this impressive therapeutic landscape and discusses how to choose the best ones for the individual MS patient.

    Visit www.morningcommutepodcast.com/ms7 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

    続きを読む 一部表示
    1分未満
  • S6:E2 – Neurology Morning Commute: Covid-19 Vaccines and Disease-Modifying Treatments for MS
    2022/03/18
    Are there issues with getting the Covid-19 vaccine and boosters for patients with MS who are on disease-modifying therapies? In this podcast our faculty discuss the safety and efficacy of the vaccines, timing with disease-modifying therapies, and monoclonal antibodies for prevention and treatment.
    続きを読む 一部表示
    1分未満